By Kosaku Narioka
Takeda Pharmaceutical is scheduled to report third-quarter results on Thursday. Here's what you need to know:
NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data provider LSEG. That would compare with Y105.7 billion net profit in the year-earlier period.
REVENUE FORECAST: Third-quarter revenue is estimated to have grown 2.4% from a year earlier to Y1.138 trillion, according to the LSEG poll.
The stock has declined 0.7% so far this year to close at Y4,153 on Wednesday, following a 3.1% gain in 2024.
WHAT TO WATCH:
--For the fiscal year ending March, Takeda has projected that revenue will increase 5.1% to Y4.480 trillion and net profit will drop 53% to Y68.00 billion. Investors will be closely watching for any changes to the annual guidance.
--Second-quarter sales of ulcerative colitis drug Entyvio climbed 20% to Y238.9 billion and sales of plasma-derived products rose 20% to Y264.2 billion. Investors will be focusing on the pace of sales growth for key drugs.
--The company's operating profit margin improved to 15.7% in its second quarter from 13.8% the previous quarter. Investors will be paying attention to margin trends as businesses globally are dealing with relatively high inflation.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
January 29, 2025 04:10 ET (09:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.